Dear Customer,
Important Information Regarding Mounjaro®▼ (tirzepatide)
Eli Lilly & Company will be adjusting the UK list price for Mounjaro, to bring it into line with the rest of Europe and other developed countries. This will be effective from 1st September 2025.
Lilly understands that changes in medicine pricing can be challenging, and want to support patients and healthcare organisations through this transition. To assist with your understanding and next steps, Lilly have shared the below information.
Why are Lilly increasing Mounjaro prices?
Following a review, Lilly will increase the UK list price for Mounjaro from 1st September to address pricing inconsistencies compared to other developed countries, including in Europe. In parallel, Lilly have reached an agreement with the NHS to ensure continued supply and patient access. While Lilly does not determine the prices that private healthcare providers set, Lilly are working with them to maintain patient access.
The UK was one of the first countries where Lilly launched Mounjaro, and the priority was to bring it to patients as quickly as possible during a time of limited supply of GLP-1 RA treatments for type 2 diabetes. At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS availability. With changes in the environment and new clinical evidence supporting the value of Mounjaro, Lilly are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation.
Why does the UK price need to be in line with European and other developed countries average prices?
Having a significantly lower price in the UK than European countries encourages other entities to export UK supply to those countries to profit from the price differential. Although this practice is banned to protect supply for UK patients, Lilly are aware of attempts to circumvent the export ban. Illegal exports could jeopardise patient safety by compromising the supply chain and Lilly are taking all means possible to protect UK supply for UK patients.
What are the new UK List Prices of Mounjaro?
Mounjaro®▼ (tirzepatide) KwikPen® Dose Updated UK List Price 2.5mg £133 5mg £180 7.5mg £255 10mg £255 12.5mg £330 15mg £330
Will the NHS be paying the new list prices?
Lilly has reached an agreement with the NHS to maintain patient access across all care settings, as such the cost effectiveness of Mounjaro per NICE and SMC guidance has remained unchanged. For any further queries on the reimbursement mechanism or timelines kindly refer to official communication from NHS England, NHS Scotland, NHS Wales, or NHS Northern Ireland.
How are Lilly supporting private providers to maintain patient access to Mounjaro?
To maintain patient access to Mounjaro, Lilly will be providing commercial terms to all private providers. These commercial terms are expected to be transferred to patients. Lilly will continue to assess the Commercial Agreement.
Lilly will be requesting each private provider to submit a monthly breakdown of NHS and private prescriptions/sales. This data will be used for high-level calculations related to the monthly rebates, and submissions should be provided no later than the end of each month.
To view The Commercial Agreement please see the propositions page within your AAH account via this link.
If you have any queries and would like to directly get in contact with Lilly – please email, who will be able to support.
Kind Regards,
AAH Pharmaceuticals